Drug interactions
Lumefantrine + Zafirlukast
Severity: Minor
Lumefantrine and Zafirlukast: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Zafirlukast is a weak CYP3A4 inhibitor, and lumefantrine is a CYP3A4 substrate. Lumefantrine levels may rise slightly, which could add to QT prolongation risk. The effect is expected to be small.
What this interaction means in plain words
Lumefantrine and Zafirlukast have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Why it happens
Weak inhibition of CYP3A4-mediated lumefantrine metabolism by zafirlukast.
What to do
No routine adjustment is needed. Consider ECG monitoring if other QT-prolonging drugs or electrolyte disturbances are present.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Lumefantrine and Zafirlukast, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Zafirlukast
- Pimozide + Zafirlukast Contraindicated
- Lomitapide + Zafirlukast Major
- Nilotinib + Zafirlukast Major
- Warfarin + Zafirlukast Major
- Apalutamide + Zafirlukast Moderate
- Carbamazepine + Zafirlukast Moderate
Frequently asked questions
Can I take Lumefantrine with Zafirlukast?
MediHelp rates the interaction as minor. Lumefantrine and Zafirlukast have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Zafirlukast is a weak CYP3A4 inhibitor, and lumefantrine is a CYP3A4 substrate. Lumefantrine levels may rise slightly, which could add to QT prolongation risk. The effect is expected to be small.
How serious is the interaction between Lumefantrine and Zafirlukast?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: No routine adjustment is needed. Consider ECG monitoring if other QT-prolonging drugs or electrolyte disturbances are present.
What other medicines interact with Zafirlukast?
MediHelp also lists interactions of Zafirlukast with, for example, Pimozide, Lomitapide, Nilotinib. The full list is on the Zafirlukast page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
